> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-017.md).
# BRE 017
## Electric Fields and Mitotic Checkpoint Inhibition in Brain Cancer
**Clinical Cancer Name:** Glioblastoma
**Common Cancer Name:** Brain Cancer
## Source
Kessler, A. F., Frömbling, G. E., Gross, F., et al. (2018).
*Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition.*
*Cell Death Discovery, 4, 77.*
***
## BRS Score
**BRS:** 8.4 / 10\
**STEMD:** S9 / T8 / E8 / M9 / D8\
**External Evidence Level:** Moderate experimental combination-mechanism evidence
## Score Interpretation
BRE-017 receives a strong BRS because it provides experimental evidence that TTFields effects on glioblastoma cells can be enhanced by mitotic checkpoint inhibition. Its strongest value is the connection between TTFields-induced mitotic stress and cell-cycle checkpoint vulnerability.
***
## Entry Summary
BRE-017 asks a new question in the TTFields pathway:
Can electric-field effects become stronger when cancer cells lose their ability to manage mitotic stress?
Glioblastoma cells, like other cancer cells, depend on cell-cycle checkpoints to survive stress during division. These checkpoints help the cell pause, correct errors, or avoid catastrophic failure.
This study suggests that when mitotic checkpoint control is inhibited, TTFields-induced stress may become more damaging to glioblastoma cells.
In simple language:
TTFields may push dividing brain cancer cells into stress. If the cell’s safety-check system is weakened, that stress may become harder for the cancer cell to survive.
***
## What BREXAtlas Found
BREXAtlas identifies BRE-017 as a combination-amplification entry.
The extracted mechanism chain is:
TTFields\
↓\
Mitotic stress\
↓\
Checkpoint inhibition\
↓\
Increased mitotic instability\
↓\
Enhanced tumor-cell death
This makes BRE-017 important because it suggests TTFields may be more effective when paired with interventions that weaken cancer-cell checkpoint defenses.
***
## Questions This BRE Helps Answer
What is a mitotic checkpoint?
A mitotic checkpoint is a safety system cells use during division.
It helps ensure chromosomes are properly organized before the cell continues dividing.
**What BREXAtlas found:**\
BRE-017 supports that disrupting this checkpoint may make glioblastoma cells more vulnerable to TTFields.
Can TTFields be amplified by combination therapy?
**What BREXAtlas found:**\
Yes, in this experimental glioblastoma model, TTFields effects were enhanced by mitotic checkpoint inhibition.
This supports the idea that TTFields may not only function as a standalone intervention, but also as part of a combination strategy.
Why does this matter for brain cancer?
Glioblastoma is difficult to treat because it adapts, resists therapy, and continues dividing aggressively.
BRE-017 suggests one possible strategy:
Target the division process with TTFields while also weakening the cancer cell’s ability to survive division errors.
***
## Study Classification
| Category | Classification |
| ------------------------------ | ------------------------------------------- |
| Study Type | Experimental combination-mechanism study |
| Cancer Focus | Glioblastoma |
| Common Cancer Name | Brain cancer |
| Treatment Type | TTFields plus mitotic checkpoint inhibition |
| Direct Electric-Field Evidence | Yes |
| Direct Mechanism Evidence | Yes |
| Combination Evidence | Yes |
| Mechanism Index Suitability | Yes |
| Pattern Tracker Suitability | Yes |
***
## Mechanisms
### MEC-019: Spindle Assembly Checkpoint Disruption
The spindle assembly checkpoint helps cells avoid division errors.
BRE-017 supports that inhibiting this checkpoint can amplify TTFields-induced stress.
### MEC-017: Mitotic Catastrophe Enhancement
TTFields may push dividing cancer cells toward mitotic failure, and checkpoint inhibition may intensify that process.
### MEC-054: Combination Amplification
BREXAtlas classifies this as a combination-amplification mechanism because the effect depends on interaction between TTFields and another vulnerability.
### MEC-055: Cell-Cycle Vulnerability
Cancer cells may be vulnerable when their cell-cycle control systems are disrupted during TTFields exposure.
***
## Discovery
### DISC-009: TTFields Combination Amplification Through Checkpoint Weakness
BRE-017 supports the discovery that TTFields effects may be enhanced by targeting mitotic checkpoint vulnerabilities.
This discovery connects directly to the broader BREXAtlas idea that electric-field therapy may become more powerful when paired with treatments that expose or intensify cancer-cell weaknesses.
***
## Connections to Other BRE Entries
### Connected to BRE-014
BRE-014 showed that TTFields can disrupt mitotic spindle organization and chromosome segregation.
BRE-017 extends this by suggesting that checkpoint inhibition may make those mitotic errors more damaging.
### Connected to BRE-015
BRE-015 showed septin mislocalization and abnormal mitotic exit.
BRE-017 adds that interfering with cell-cycle checkpoints may amplify structural division failure.
### Connected to BRE-016
BRE-016 focused on cytokinetic vulnerability during late-stage division.
BRE-017 complements this by showing that checkpoint weakness may increase vulnerability to TTFields-induced mitotic stress.
### Connected to BRE-003
BRE-003 showed TTFields may enhance radiation effects by delaying DNA repair.
BRE-017 shows another combination logic: TTFields plus mitotic checkpoint inhibition.
Together, these entries support the broader question of whether TTFields can amplify other cancer treatments.
### Connected to BRE-004
BRE-004 showed that TTFields may enhance chemotherapy response in pancreatic cancer models.
BRE-017 strengthens the general combination-treatment pathway by focusing specifically on mitotic checkpoint vulnerability in glioblastoma.
***
## Research Gaps Identified
* **RG-082: Combination Specificity Gap**\
Which checkpoint inhibitors produce the strongest TTFields amplification?
* **RG-083: Glioblastoma Translation Gap**\
Do these experimental findings translate into meaningful clinical outcomes for glioblastoma patients?
* **RG-084: Timing Gap**\
What timing or sequence works best: TTFields before checkpoint inhibition, after checkpoint inhibition, or simultaneous treatment?
* **RG-085: Safety Gap**\
Can checkpoint inhibition increase TTFields effects on tumor cells without increasing unacceptable harm to normal dividing cells?
* **RG-086: Cross-Cancer Checkpoint Gap**\
Does TTFields amplification through checkpoint vulnerability apply only to glioblastoma, or can it extend to other cancers?
***
## Why This Entry Matters
For researchers, BRE-017 introduces an important combination strategy: use TTFields to create mitotic stress, then weaken the cancer cell’s ability to survive that stress.
For patients and families, the core idea is simple:
Some cancer treatments may work better when cancer cells lose their ability to repair or manage the damage caused by treatment.
BRE-017 does not prove this approach is ready for routine care. It shows that the combination question is scientifically meaningful.
***
## Entry Conclusion
BRE-017 expands the TTFields mechanism pathway from structural disruption to combination amplification.
BRE-014 showed that TTFields disrupt mitotic structures.
BRE-015 showed disruption of septins and mitotic exit.
BRE-016 showed vulnerability during late-stage cell division.
BRE-017 shows that weakening the mitotic checkpoint may make TTFields effects stronger.
The central question emerging from this entry is:
Can TTFields become more effective when paired with treatments that weaken cancer-cell division checkpoints?
For BREXAtlas, BRE-017 is a key bridge between mechanism evidence and future combination-treatment strategy.
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://www.brexatlas.org/bre-001/bre-017.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.